The manufacturer received a notification of a device related adverse event recorded in a scientific paper.Ann thorac surg.2018 mar;105(3):e103-e105.Doi: 10.1016/j.Athoracsur.2017.10.001.Mitral regurgitation exacerbation due to sutureless aortic valve replacement.Lee t1, mittnacht ajc2, itagaki s3, stewart a3.(b)(6) event summary: a patient with aortic stenosis was to receive an avr using a perceval pvs21 aortic heart valve.In the abstract it states, ¿however, this implantation resulted in the exacerbation of mitral regurgitation.The sutureless valve required explantation, and a traditional sutured valve was subsequently implanted, which returned the mitral regurgitation to baseline.¿ the perceval valve was explanted and replaced with a magna ease (edwards lifesciences, (b)(4)) aortic valve.
|
The manufacturer received further information on may 29, 2018.The operating physician informed the manufacturer that the valve was positioned too low.His assistant didn¿t have proper tension on the guiding sutures.The manufacturer will not be investigating the case any further.No device malfunction was identified and the root cause can be attributed to operational context.Changed fields: date of report, pma/510k and follow-up, what type.
|